Obermatt
See Similar Stocks →

Context Therapeutics

NAQ:CNTX · US21077P1084
PharmaceuticalsSmall

360° View

no current rank
Price/Sales—
Price/Earnings48
Price/Book16
Dividend Yield—
Revenue Growth—
Profit Growth75
Capital Growth98
TSR 52w84
Leverage75
Liquidity70
Refinancing48
Combined—
Analyst Opinions61
Pro Holdings33
Opinion Changes14
Market Pulse39

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2015
Employees24
Websitecontexttherapeutics.com
ISINUS21077P1084
Last UpdateApr 2, 2026
Index & Theme
ImmunologyOncologyBiotechnology

Description

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing T cell engaging (‘TCE’) bispecific antibodies (‘bsAb’) for solid tumors. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claud…

Similar Stocks

The companies this stock is ranked against.

Compare Context Therapeutics with its peers
CytomX Therapeutics
NSQ:CTMX
8
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Bicara Therapeutics
NMQ:BCAX
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prestige Consumer Healthcare
NYQ:PBH
60
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Beyondspring
NAQ:BYSI
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →